

DEPARTMENT OF HEALTH AND HUMAN SERVICES

DHHS

Stacie Weeks, JD MPH Administrator

DIVISION OF HEALTH CARE FINANCING AND POLICY Helping people. It's who we are and what we do.

Drug Utilization Review

Board Meeting Minutes

Date of Meeting: Thursday, January 19, 2023

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP),

Drug Use Review Board

Agenda Item	Record			Notes
1. Call to Order and Roll Call				 DHCFP Staff Present were as follows: Griffin, Karen, Senior Deputy Attorney General (SDAG)
	January 19, 2023.	Chairperson Wheeler called the meeting to order at 1:12 p.m. on January 19, 2023.		
	Chairperson Wheeler took the roll.			Gudino, Antonio, Manager of Pharmacy Services
		Present	Absent	Clemons, Roshanda, Medical Director
	 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair 	\boxtimes		Berntson, Kindra, Social Services Program Specialist II (SSPS II), Pharmagy Unit
	Mark Canty, MD		\boxtimes	Pharmacy UnitFlowers, Ellen, Program Officer I,
	Crystal Castaneda, MDJessica Cate, Pharm.D.		\boxtimes	Pharmacy Unit
	Dave England, Pharm.D. Prain Lo. DO.	\boxtimes		Magellan Rx Staff Present were as follows:
	Brain Le, DORebecca Sparks, PA-C		\boxtimes	Mishra, Raj, Pharm.D., Clinical Account
	Jim Tran, Pharm.D.			ManagerKim, James, Pharm.D., Dir. Clinical Account Services

			 Martinez, Chris, Sr. Business Analyst Chow, Connie, Pharm.D., Clinical Account Manager Killpack, Andy, Pharm.D., Dir. Specialty Clinical Solutions Managed Care Organization representatives present were as follows: Lim, Luke, Pharm.D., Anthem Bitton, Ryan, Pharm.D., Health Plan of Nevada Miro, Trashelle, Pharm.D., Silver Summit Health Plan Tran, Jimmy, Pharm.D., Molina Healthcare The public attendee list is included as Attachment A. Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list's accuracy is not assured.
2.	General Public Comment	Telephonic and web comment was called for, and the phone lines were opened.	
		No public comment was provided.	
3.	Administrative		
	a. For Possible Action: Review and Approve Meeting Minutes from October 20,	Board Member Netochi moved to approve the minutes as presented, and Board Member England seconded the motion.	
	2022	A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):	

	1					
			Yes	No	Abst.	
	 Jenni 	fer Wheeler, Pharm.D., Chair	\boxtimes			
	 Neto 	chi Adeolokun, Pharm.D., Vice Chair	\boxtimes			
	 Mark 	Canty, MD			\boxtimes	
	Cryst	al Castaneda, MD			\boxtimes	
	 Jessic 	ca Cate, Pharm.D.			\boxtimes	
	 Dave 	England, Pharm.D.	\boxtimes			
	Brain	Le, DO	\boxtimes			
	• Rebe	cca Sparks, PA-C			\boxtimes	
	• Jim T	ran, Pharm.D.	\boxtimes			
b. Status Update by DHCFP	Chief of I	Pharmacy Services David Olsen provid	ded fiv	е		
	announc	ements.				
	• The d	livision would like to welcome Doctor	Rosha	anda Cl	emons as	
	the n	ew Medicaid Medical Director.				
	• The d	livision would also like to thank and r	ecogni	ze Doc	tor	
	Mich	ael Owens. He recently resigned his b	oard p	osition	with the	
	Drug	Utilization Review Board. We are also	o acce	oting re	esumes	
	and C	CVs from health providers for board n	nembe	rs for k	oth	
	board	ds the Drug Utilization Review Board	and Sil	ver Sta	te Scripts	
	Board	d. If there's interest, you can e-mail p	harma	cy serv	ices at	
	RXinf	o@dhcfp.nv.gov				
	 Neva 	da Medicaid has established licensed	pharn	nacists	as a new	
	provi	der type. Services related to dispensi	ng self	-admir	istered	
	contr	aceptives and prescribing HIV prever	ition m	edicat	ions are	
	now	reimbursable when provided by a pha	armaci	st enro	lled	
	Neva	da Medicaid provider. For more infor	w to			
	enrol	l as a Nevada Medicaid provider, plea				
	enrol	lment page that's found at the websi				
	www	.medicaid.nv.gov.				
	Neva	da Medicaid is working on a project t	o man	age pro	ovider	
	admi	nistered drugs. Prior authorizations w	ill be ر	equire	d for a list	
	of 60	specialty drugs. It is tentatively sched	duled t	o impl	ement as	

	soon as April 24 th , 2023, and subject to change. This project is specific to only fee-for-service.	
4. Clinical Presentations	,	
a. For Possible Action:		
Discussion and possible		
adoption of prior		
authorization criteria and/or		
quantity limits for NUCALA		
and DUPIXENT.		
i. <u>Public comment</u> on	Telephonic and web comment was called for, and the phone lines	
proposed clinical prior	were opened.	
authorization criteria.	Nie wyddia acananaut ywa gan iddad	
ii. Presentation of	No public comment was provided. Dr. Raj Mishra provided the clinical background and indications for	
utilization and clinical	NUCALA and DUPIXENT.	
information.	NOCALA UNU DOI IXLIVI.	
illionilationi	Dr. Mishra reviewed the proposed criteria presented in the binder	
	and discussed the utilization of Nucala and Dupixent.	
	Dr. Lim with Anthem, approved of the proposed criteria and	
	utilization presented.	
	Dr. Bitton with Health Plan of Nevada, approved of the proposed	
	criteria and utilization presented.	
	Dr. Miro with Silver Summit Health Plan, approved of the	
	proposed criteria and utilization presented.	
	Dr. Tran with Molina Healthcare, approved of the proposed	
:: Discussion by Doord and	criteria and utilization presented.	
iii. Discussion by Board and review of utilization	Chairperson Wheeler asked for comments from the Board Members.	
data.	No comments were made.	
iv. Proposed adoption of	Board Member Tran moved to approve the criteria as presented by	
updated prior	Magellan, and Board Member Adeolokun seconded the motion.	
authorization criteria.	magenary and sourd member rises on an seconded the motion.	
	A vote was taken, and the results were as follows from members in	

	attendance (in favor, against, and abstentions				
	 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Mark Canty, MD Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	Yes	No	Abst.	
b. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for PENICILLAMINE.					
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, were opened. No public comment was provided.	and the	e phor	ne lines	
ii. Presentation of utilization and clinical information.	 Dr. Mishra provided the clinical background ar PENICILLAMINE. Dr. Mishra reviewed the proposed criteria pre and discussed the utilization for Penicillamine. Dr. Lim with Anthem, approved of the pro utilization presented. 	Dr. Mishra provided the clinical background and indications for PENICILLAMINE. Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Penicillamine. • Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.			

			Dr. Miro with Silver Summit Health Plan, a	nnrov	ed of th	 ne				
			proposed criteria and utilization presente		ca or ti	ic .				
			Dr. Tran with Molina Healthcare, approve		e nron	nsed				
			criteria and utilization presented.	a 01 tii	с ргор	oscu				
	iii. C	Discussion by Board and	Chairperson Wheeler asked for comments fro	m the	Board	Memhers				
		eview of utilization	·	iii tiic	Doard	Wichibers.				
		lata.	No comments were made.							
		Proposed adoption of	Board Member Le moved to approve the crite	ria as	present	ted by				
		updated prior outhorization criteria.	Magellan, and Board Member England second	ded the	e motic	on.				
			A vote was taken, and the results were as follo	ws fro	om mer	mbers in				
			attendance (in favor, against, and abstention	wher	e appli	cable):				
				Yes	No	Abst.				
			Jennifer Wheeler, Pharm.D., Chair	\boxtimes						
			Netochi Adeolokun, Pharm.D., Vice Chair	\boxtimes						
			Mark Canty, MD			\boxtimes				
			Crystal Castaneda, MD			\boxtimes				
			Jessica Cate, Pharm.D.			\boxtimes				
			Dave England, Pharm.D.	\boxtimes						
			n	\boxtimes						
			•	_						
			Rebecca Sparks, PA-C Repaire Decrease							
			Jim Tran, Pharm.D.	\boxtimes	Ш					
c.		ssible Action:								
		sion and possible								
	•	on of prior								
		ization criteria and/or								
	•	ty limits for RAYALDEE								
	•	FEDIOL).								
	·	Public comment on	Telephonic and web comment was called for,	and th	ne phor	ne lines				
		proposed clinical prior	were opened.							
	а	uthorization criteria.								

		No public comment was provided.				
ii.	Presentation of	Dr. Mishra provided the clinical background ar	d indi	cations	for	
	utilization and clinical information.	RAYALDEE (CALCIFEDIOL).				
		Dr. Mishra reviewed the proposed criteria pres	ented	l in the	binder	
		and discussed the utilization for RAYALDEE (CA	LCIFE	DIOL).		
		Dr. Lim with Anthem, approved of the pro- utilization presented.				
		Dr. Bitton with Health Plan of Nevada, app	roved	of the	proposed	
		criteria and utilization presented.Dr. Miro with Silver Summit Health Plan, a	anrov	nd of th	10	
		proposed criteria and utilization presented	•		ie	
		recommendation of adding the following of			does not	
		exceed 60 MCG (2capsules) per day.				
		Dr. Tran with Molina Healthcare, approved	of the	e propo	osed	
		criteria and utilization presented.				
iii.	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from	n the I	Board I	Members.	
		No comments were made.				
iv.	Proposed adoption of	Board Member Tran moved to approve the cri	teria a	s prese	ented by	
	updated prior authorization criteria.	Magellan, and Board Member England second	ed the	e motio	n.	
		A vote was taken, and the results were as follo attendance (in favor, against, and abstentions				
			Yes	No	Abst.	
		Jennifer Wheeler, Pharm.D., Chair	\boxtimes			
		Netochi Adeolokun, Pharm.D., Vice Chair	\boxtimes			
		Mark Canty, MD			\boxtimes	
		Crystal Castaneda, MD			\boxtimes	
		Jessica Cate, Pharm.D.			\boxtimes	
		Dave England, Pharm.D.	\boxtimes			

	Brain Le, DO	
	Rebecca Sparks, PA-C	
	• Jim Tran, Pharm.D.	
d. For Possible Action:		
Discussion and possible		
adoption of prior		
authorization criteria and/o		
quantity limits for RELYVRIC		
(SODIUM		
PHENYLBUTYRATE/TAURUR	5	
ODIOL).		
i. <u>Public comment</u> on	Telephonic and web comment was called for, and the phone lines	
proposed clinical prior	were opened.	
authorization criteria.		
	No public comment was provided.	
ii. Presentation of	Dr. Mishra discussed the new drug update and provided clinical	
utilization and clinical	background for RELYVRIO (SODIUM PHENYLBUTYRATE/	
information.	TAURURSODIOL).	
	Dr. Michra reviewed the proposed criteria presented in the hinder	
	Dr. Mishra reviewed the proposed criteria presented in the binder	
	and discussed the utilization of RELYVRIO (SODIUM PHENYLBUTYRATE/TAURURSODIOL)	
	PHENTLEOTTRATE/TAURURSODIOL)	
	Dr. Lim with Anthem, approved of the proposed criteria and	
	utilization presented.	
	 Dr. Bitton with Health Plan of Nevada, approved of the proposed 	
	criteria and utilization presented.	
	Dr. Miro with Silver Summit Health Plan, approved of the	
	proposed criteria and utilization presented.	
	 Dr. Tran with Molina Healthcare, approved of the proposed 	
	criteria and utilization presented.	
	Citteria and utilization presented.	

iii.	Discussion by Board and review of utilization data. Proposed adoption of updated prior authorization criteria.	Chairperson Wheeler asked for comments from No comments were made. Board Member Le moved to approve the criter Magellan, and Board Member Trans seconded A vote was taken, and the results were as followattendance (in favor, against, and abstentions)					
		 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Mark Canty, MD Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	Yes	No	Abst.		
Dis add aut qua	r Possible Action: scussion and possible option of prior thorization criteria and/or antity limits for GFILGRASTIM.						
i.	Public comment on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, were opened. Ben Droese pharmacist with Amgen medical a comment.		•			

ii.	Presentation of utilization and clinical	Dr. Killpack provided the clinical background a PEGFILGRASTIM.	nd ind	ication	s for
	information.	PEGFILGRASTIIVI.			
		Dr. Killpack reviewed the proposed criteria pre	sente	d in the	e binder
		and discussed the utilization of PEGFILGRASTII	M.		
		Dr. Lim with Anthem, approved of the pro	nacad	critoria	a and
		utilization presented.	poseu	CITCETTO	a ariu
		Dr. Bitton with Health Plan of Nevada, app	roved	of the	proposed
		criteria and utilization presented.			
		Dr. Miro with Silver Summit Health Plan, a proposed criteria and utilization proceeds.		ed of th	ne
		proposed criteria and utilization presented Dr. Tran with Molina Healthcare, approved of t		posed	criteria
		and utilization presented.			
iii.	Discussion by Board and	Chairperson Wheeler asked for comments fro	m the	Board	Members.
	review of utilization data.	No comments were made.			
iv.	Proposed adoption of	Board Member Tran moved to approve the cri	teria a	s prese	ented by
	updated prior	Magellan, and Board Member Adeolokun seco		•	•
	authorization criteria.		•		
		A vote was taken, and the results were as follo attendance (in favor, against, and abstentions			
		attendance (in ravor, against, and abstentions	WITCH	с аррік	cable).
			Yes	No	Abst.
		Jennifer Wheeler, Pharm.D., Chair	\boxtimes		
		Netochi Adeolokun, Pharm.D., Vice Chair			
		Mark Canty, MD Crystal Castanada, MD			\boxtimes
		Crystal Castaneda, MDJessica Cate, Pharm.D.			\boxtimes
		Dave England, Pharm.D.			
		Brain Le, DO	\boxtimes		
		Rebecca Sparks, PA-C			\boxtimes
		Jim Tran, Pharm.D.	\boxtimes		

Di ad au qu	or Possible Action: iscussion and possible doption of prior uthorization criteria and/or uantity limits for ARANESP DARBEPOETIN ALFA).		
i.	Public comment on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided.	
ii.	Presentation of utilization and clinical information.	 Dr. Killpack provided the clinical background and indications for ARANESP (DARBEPOETIN ALFA) Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization for ARANESP (DARBEPOETIN ALFA). Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
iii.	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.	
iv.	Proposed adoption of updated prior authorization criteria.	Board Member Le moved to approve the criteria as presented by Magellan, and Board Member Tran seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):	

	 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Mark Canty, MD Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	Yes	No	Abst.	
g. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for DENOSUMAB (PROLIA, XGEVA).					
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, as were opened. No Public comment was provided.	nd the	phon	e lines	
ii. Presentation of utilization and clinical information.	 Dr. Killpack provided the clinical background and DENOSUMAB (PROLIA, XGEVA). Dr. Killpack reviewed the proposed criteria prese and discussed the utilization of DENOSUMAB (Proposed criteria presented). Dr. Lim with Anthem, approved of the proputilization presented. Dr. Bitton with Health Plan of Nevada, approcriteria and utilization presented. 	ented ii ROLIA, I	n the XGEV riteria	binder A). and	

iii.	Discussion by Board and review of utilization	 Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. Chairperson Wheeler asked for comments from the Board Members. 				
iv.	data. Proposed adoption of updated prior authorization criteria.	No comments were made. Board Member Tran moved to approve the criteria as presented by Magellan, and Board Member England seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):				
		 Jennifer Wheeler, Pharm.D., Chair Netochi Adeolokun, Pharm.D., Vice Chair Mark Canty, MD Crystal Castaneda, MD Jessica Cate, Pharm.D. Dave England, Pharm.D. Brain Le, DO Rebecca Sparks, PA-C Jim Tran, Pharm.D. 	Yes	No	Abst.	
Dis ad au qu	r Possible Action: scussion and possible option of prior thorization criteria and/or antity limits for OCREVUS CRELIZUMAB).					

i.	Public comment on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, a were opened. No Public comment was provided.	and th	e phon	e lines	
ii.	Presentation of utilization and clinical information.	Dr. Killpack discussed the indication for the ne OCREVUS (OCRELIZUMAB).				
		Dr. Killpack reviewed the proposed criteria pre and discussed the utilization of OCREVUS (OCF				
		 Dr. Lim with Anthem, approved of the pro- utilization presented. 				
		Dr. Bitton with Health Plan of Nevada, app criteria and utilization presented.				
		 Dr. Beranek with Silver Summit Health Plan proposed criteria and utilization presented Dr. Tran with Molina Healthcare, approved of 				
		and utilization presented.				
iii.	Discussion by Board and review of utilization	Chairperson Wheeler asked for comments fro	m the	Board	Members.	
	data.	No comments were made.				
iv.	Proposed adoption of updated prior authorization criteria.	Board Member Adeolokun moved to approve the criteria as presented by Magellan, and Board Member Le seconded the motion.				
		A vote was taken, and the results were as folloattendance (in favor, against, and abstentions				
			Yes	No	Abst.	
		 Jennifer Wheeler, Pharm.D., Chair 	\boxtimes			
		Netochi Adeolokun, Pharm.D., Vice Chair	\boxtimes			
		Mark Canty, MD			\boxtimes	
		Crystal Castaneda, MD			\boxtimes	
		 Jessica Cate, Pharm.D. 			\boxtimes	

	◆ Dave England, Pharm.D. □ □ □	
	● Brain Le, DO 🖂 🗆 🗆	
	Rebecca Sparks, PA-C	
	● Jim Tran, Pharm.D. 🖂 🗆 🗆	
5. DUR Board Requested Reports		
a. Opioid Reports:	Dr. Mishra presented opioid utilization reports.	
i. Opioid Trends	Dr. Lim presented opioid utilization reports.	
ii. Count of Claims	Dr. Bitton presented opioid utilization reports.	
iii. Med Trend	Dr. Miro presented opioid utilization reports.	
iv. Top Members	Dr. Tran presented opioid utilization reports.	
v. Top Ten Prescribers		
vi. MED		
b. Standard DUR Reports:	Dr. Mishra presented Standard DUR Reports	
i. Top 10 Classes by	Dr. Lim presented Standard DUR Reports.	
amount paid	Dr. Bitton presented Standard DUR Reports	
ii. By Claim Count	Dr. Miro presented Standard DUR Reports	
iii. cDUR Quarterly Report	Dr. Tran presented Standard DUR Reports.	
iv. cDUR Detail Activity		
Summary		
v. cDUR Detailed Saving		
Outcome		
vi. Retro DUR		
6. Closing Discussion		
a. Public Comment	Telephonic and web comment was called for, and the phone lines	
	were opened.	
	Public comment was provided by Amy Hale Principal Scientific	
	account with Scientific Affairs and pharmacist in Nevada for	
	Ketamine or Spravato.	
b. For Possible Action: Date	Chairperson Wheeler stated the next meeting is scheduled for April	
and location of the next	20, 2023.	
meeting.		
	Location: Hilton Garden Inn Reno	

c. Adjournment The meeting adjourned at 2:38 p.m.

Attachment A – Members of the Public in Attendance

Budsberg, Scott	Yip, Brandon /US	Cheryl Donahue	Karen Ou
Joe Germain Jr.	Lea Case	Craig Irwin	Roa, Ryan A
Crecco, Jason	Harrison, Emily	Sommers, Melissa	Warner Quon
Gary Parenteau	Droese, Ben	Michael Zarob	Chris G
Nicholas Boyer	GNH (Gina Heinen)	Colabianchi, Jeana	Deb Guay
Michael Pazirandeh	Susan Hertzberg	Todd Dickerson	
Gittinger William	Wright, Kelly	Zimmer, Eileen	
Joe Gelinas	Kelvin Yamashita	John E Davis	
Mike Turk	Mark Germann	Monz, Dana	
Pulver, Lisa [JANUS]	Valerie D Ng	Christina Hartmann	

Attachment B – Submitted Written Comment

No written comments submitted